2 unchanged sentences
(1) that the equipment used to manufacture ibrexafungerp was also used to manufacture a non-antibacterial beta-lactam drug substance, presenting a risk of cross-contamination;
−Removed: (2) that we did not have effective internal controls and procedures, as well as adequate internal oversight policies to ensure that its vendor complied with current Good Manufacturing Practices (cGMP);
+Added: (2) that we did not have effective internal controls and procedures, as well as adequate internal oversight
+Added: policies to ensure that its vendor complied with current Good Manufacturing Practices (cGMP);
(3) that, due to the substantial risk of cross-contamination, we were reasonably likely to recall its ibrexafungerp tablets and halt its clinical studies;
1 unchanged sentence
The complaint seeks unspecified damages, interest, fees and costs on behalf of all persons and entities who purchased and/or acquired shares of our common stock between March 31, 2023 to September 22, 2023.
−Removed: We disagree with the allegations and intend to defend the litigation vigorously .
+Added: We have filed a motion to dismiss.
+Added: On May 1, 2024, and again on June 4, 2024, purported shareholder derivative complaints were filed in the United States District Court, District of New Jersey.
+Added: The complaints name our directors and certain of our officers and assert state and federal claims based on the same alleged misstatements as the securities class action complaint.
+Added: These cases were consolidated and are currently stayed.
+Added: We disagree with the allegations and we intend to defend these litigations vigorously .
MINE SAF ETY DISCLOSURES
1 unchanged sentence
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.